Dan­ish com­pa­ny pays $145M up­front to li­cense nasal spray al­ter­na­tive to EpiPen

A Dan­ish com­pa­ny is spend­ing $145 mil­lion up­front for cer­tain rights to the first-ever nee­dle-free adren­a­line nasal spray for se­vere al­ler­gic re­ac­tions, un­lock­ing sales po­ten­tial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER